Kalp Kapak Ekokardiyografisi
Özet
Kalp kapak hastalıkları, erken evrelerde asemptomatik seyredebileceği gibi ilerleyen aşamalarda nefes darlığı, senkop ve hemodinamik instabilite gibi ciddi semptomlara ve kalp yetmezliğine yol açabilir. Tanı ve takipte birinci basamak tanısal yöntem olarak transtorasik ekokardiyografi (TTE) önerilmektedir. Sol kalpte aort yetersizliği, aort stenozu, mitral yetersizliği ve mitral stenozu gibi patolojiler izlenirken; sağ kalpte triküspid yetmezliği, triküspid stenozu, pulmoner yetmezlik ve pulmoner stenoz görülür. Aort yetersizliği ve darlığında gri skala ile renkli Doppler yöntemleri, jet akımı ve basınç gradientleri incelenerek evreleme yapılır. Mitral kapak patolojilerinde sol ventrikül ve sol atriyumda volüm ile basınç artışları meydana gelir; romatizmal mitral darlığında belirgin hokey sopası bulgusu izlenir. Triküspid ve pulmoner kapak hastalıkları ise genellikle sekonder nedenlere veya sol kalp patolojilerine bağlı gelişmektedir. Acil hekimleri ve kardiyoloji dışı branşlar için kapak bozukluklarının yatak başı ekokardiyografi ve renkli Doppler ile erken tanınması, kalıcı sistolik disfonksiyon gelişmeden hastaların cerrahiye yönlendirilmesi açısından kritik önem taşır.
Referanslar
Chen RS, Bivens MJ, Grossman SA.Diagnosis and management of valvular heart disease in emergency medicine.Emerg Med Clin North Am. 2011 Nov;29(4):801-10.
Siegel RJ, Luo H, Makar M, Beigel R.Optimal use of echocardiography in valvular heart disease evaluation. Heart. 2015 Jun;101(12):977-86.
Long B, Koyfman A, Gottlieb M.Management of Heart Failure in the Emergency Department Setting: An Evidence-Based Review of the Literature.J Emerg Med. 2018 Nov;55(5):635-646.
Walsh K, Hoffmayer K, Hamdan MH.Syncope: diagnosis and management.Curr Probl Cardiol. 2015 Feb;40(2):51-86.
McClung JA.Native and Prosthetic Valve Emergencies. Cardiol Rev. 2016 Jan-Feb;24(1):14-8.
Nishimura RA, Otto CM, Bonow RO et al. Guidelines., 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice. basım yeri bilinmiyor: Circulation. 2017 Jun 20;135(25):e1159-e1195.
Misfeld M, Sievers HH.Heart valve macro- and microstructure.Philos Trans R Soc Lond B Biol Sci. 2007;362(1484):1421-36.
Mrsic Z, Hopkins SP, Antevil JL, Mullenix PS.Valvular Heart Disease.Prim Care. 2018 Mar;45(1):81-94.
Akinseye OA, Pathak A, Ibebuogu UN.Aortic Valve Regurgitation: A Comprehensive Review.Curr Probl Cardiol. 2018;43(8):315-334.
Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, Iung B, Lancellotti P, Lansac E, Rodriguez Muñoz D, Rosenhek R, Sjögren J, Tornos Mas P, Vahanian A, Walther T, Wendler O, Windecker S, Zamorano JL; ESC Scientific Document Group. 2017, 2017 ESC/EACTS Guidelines for the management of valvular heart disease.Eur Heart J. ve 38(36):2739-2791.
Bonow RO, Carabello BA, Chatterjee K, et al: 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease.J Am Coll Cardiol 52: e1, 2008. [PMID:18848134].
Baumgartner H Chair, Hung J Co-Chair, Bermejo J, Chambers JB, Edvardsen T, Goldstein S, Lancellotti P, LeFevre M, Miller F Jr, Otto CM. 2017, Recommendations on the echocardiographic assessment of aortic valve stenosis: a focused update from the European Association of Cardiovascular Imaging and the American Society of Echocardiography.Eur Heart J Cardiovasc Imaging. ve 18(3):254-275.
Bakaeen FG, Rosengart TK, Carabello BA.Aortic Stenosis.Ann Intern Med. 2017;166(1):ITC1-ITC16.
Joseph J, Naqvi SY, Giri J, Goldberg S.Aortic Stenosis: Pathophysiology, Diagnosis, and Therapy.Am J Med. 2017;130(3):253-263.
Vahanian A, Iung B.Mitral regurgitation. Timing of surgery or interventional treatment.Herz. 2016;41(1):3-9. 16. Harb SC, Griffin BP.Mitral Valve Disease: a Comprehensive Review.Curr Cardiol Rep. 2017;19(8):73.
Ray R, Chambers J.Mitral valve disease.Int J Clin Pract. 2014 ;68(10):1216-20.
Nishimura RA, Vahanian A, Eleid MF, Mack MJ.Mitral valve disease--current management and future challenges.Lancet. 2016;387(10025):1324-34.
Chandrashekhar Y, Westaby S, Narula J.Mitral stenosis. Lancet. 2009 ;374(9697):1271-83.
Huttin O, Voilliot D, Mandry D, Venner C, Juillière Y, Selton-Suty C.Huttin O1, Voilliot D1, Mandry D2, Venner C1, Juillière Y1, Selton-Suty C3.Arch Cardiovasc Dis. 2016 ;109(1):67-80.
Dreyfus GD, Martin RP, Chan KM, Dulguerov F, Alexandrescu C.Functional tricuspid regurgitation: a need to revise our understanding.J Am Coll Cardiol. 2015 ;65(21):2331-6.
Hung J.The pathogenesis of functional tricuspid regurgitation.Semin Thorac Cardiovasc Surg. 2010 ;22(1):76-8.
Cevasco M, Shekar PS.Surgical management of tricuspid stenosis.Ann Cardiothorac Surg. 2017 ;6(3):275-282.
Shah PM, Raney AA.Tricuspid valve disease.Curr Probl Cardiol. 2008;33(2):47-84.
Fathallah M, Krasuski RA.Pulmonic Valve Disease: Review of Pathology and Current Treatment Options.Curr Cardiol Rep. 2017;19(11):108.
Calafiore AM, Gallina S, Iacò AL, Contini M, Bivona A, Gagliardi M, Bosco P, Di Mauro M. Mitral valve surgery for functional mitral regurgitation: should moderate-or-more tricuspid regurgitation be treated? a propensity score analysis. basım yeri bilinmiyor : Ann Thorac Surg., Cilt Ann Thorac Surg. 2009 Mar;87(3):698-703. doi: 10.1016/j.athoracsur.2008.11.028.